Eurofins Scientific (EUFI.PA): Takeaways from roadshow

Research evidence excerpt

Eurofins Scientific (EUFI.PA): Takeaways from roadshow

Equity Research

27 July 2026 | 7:41AM BST

We hosted Dr Gilles Martin, Founder and CEO, and Andrew Swift, Head of IR at Suhasini Varanasi

+44(20)7774-3722 |

Eurofins, on Friday (24 July) in our offices as part of the roadshow following the suhasini.varanasi@gs.com

Goldman Sachs International

company’s 1H26 results. Key takeaways below:

Harshita Bhatter, CFA

+1(332)245-7830 |

n Biopharma: The company indicated that the timing of recovery remains difficult harshita.bhatter@gs.com

Goldman Sachs India SPL

to forecast, with quarterly growth trends impacted by lumpiness of contracts

(e.g. Central Lab, BioPharma Product testing). The company has signed deals in

areas like CDMO and BioPharma product testing which should help deliver

improvement in growth over time. Over the medium term, management believes

that the secular growth trends remain intact - they see potential for China drug

discovery/ AI to drive an increased pipeline of molecules/products which can

support a return to normal growth rates.

n Market dynamics and competitiveness: Management discussed competitive

dynamics within each end market and believe in positioning Eurofins as one of

the leading players in each. As such the company continues to evaluate its

portfolio to decide on core vs. non-core activities. The company also sees players

exiting markets where growth has been in decline in recent years (eg.

agroscience). In discovery, ERF sees Chinese competition posing a threat, but

believes it can result in more innovative products entering the testing market in

the next few years.

n Long-term investments: management believes that several of the investments

made under the current five-year plan will start to bear fruit over the next 2–3

years: